Verinurad clinical trials
Also written RDEA3170.
- studies test it
- 17
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses verinurad is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 3 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses verinurad is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Study of Verinurad in Heart Failure With Preserved Ejection FractionCompletedPhase 2AstraZenecaNCT04327024Written as Verinurad
- Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy VolunteersCompletedPhase 1AstraZenecaNCT04532918Written as Verinurad
- A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and HyperuricaemiaCompletedPhase 2AstraZenecaNCT03990363Written as Verinurad
- A Study to Assess the Effect of Verinurad on the Electric Activity of the HeartCompletedPhase 1AstraZenecaNCT04256629Written as Verinurad
- Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With AlbuminuriaCompletedPhase 2AstraZenecaNCT03118739Written as Verinurad 9 mg+Febuxostat 80 mg
- Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic HyperuricemiaCompletedPhase 2AstraZenecaNCT02078219Written as RDEA3170
- A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese SubjectsCompletedPhase 1AstraZenecaNCT03836599Written as Verinurad
- RDEA3170 Tablet and Capsule Bioavailability StudyCompletedPhase 1Ardea Biosciences, Inc.NCT02448368Written as RDEA3170,10 mg
- Phase 2a RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedPhase 2Ardea Biosciences, Inc.NCT02498652Written as RDEA3170 2.5 mg
- RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedPhase 1Ardea Biosciences, Inc.NCT02279641Written as RDEA3170 10 mg
- RDEA3170 Bioavailability StudyCompletedPhase 1Ardea Biosciences, Inc.NCT02336594Written as RDEA3170 10 mg
- Mild, Moderate and Severe Renal Impairment StudyCompletedPhase 1Ardea Biosciences, Inc.NCT02219516Written as RDEA3170
- RDEA3170 PK/PD StudyCompletedPhase 1Ardea Biosciences, Inc.NCT02608710Written as RDEA3170 4.5 mg
- RDEA3170 Monotherapy in Subjects With GoutCompletedPhase 2Ardea Biosciences, Inc.NCT01927198Written as RDEA3170 5 mg
- A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia PatientsCompletedPhase 1/2AstraZenecaNCT02317861Written as RDEA3170
- RDEA3170 and Febuxostat Drug Interaction StudyCompletedPhase 1Ardea Biosciences, Inc.NCT01883167Written as RDEA3170 10 mg
- RDEA3170 AME StudyCompletedPhase 1Ardea Biosciences, Inc.NCT01910506Written as RDEA3170 10 mg
Given beside what is tested · 2 — verinurad is usual care or a partner of the new treatment
- A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UACompletedPhase 2AstraZenecaNCT03316131Written as Verinurad
- RDEA3170 and Febuxostat Combination Study in Gout SubjectsCompletedPhase 2Ardea Biosciences, Inc.NCT02246673Written as RDEA3170 15 mg
Codes
What other systems call verinurad · ClinicalTrials.gg INT001006
- MeSH (NLM) C000628929verinuradConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 12WJ62D047VERINURADConfirmed FDA, NLM, Wikidata
- Wikidata Q27251441verinuradConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152863VerinuradOne source FDA
- DrugBank DB11873One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628929 | verinurad | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 12WJ62D047 | VERINURAD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27251441 | verinurad | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152863 | Verinurad | One source FDA |
| DrugBank | DB11873 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.